Prophylaxis of cytomegalovirus disease in high-risk patients

Infection

Volumn 25, Issue 5, 1997, Pages 269-273

  Scholz, M ^a   Cinatl Jr , J ^a   Doerr, H W ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; DEFEROXAMINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOPTIVE IMMUNOTHERAPY; CELL TRANSPLANTATION; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; LEUKOPENIA; ORAL DRUG ADMINISTRATION; PATHOLOGY; SHORT SURVEY; T LYMPHOCYTE; VACCINATION;

ADOPTIVE TRANSFER; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; VACCINATION;

EID: 0030865691     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01720395     Document Type: Short Survey

References (55)

1. Naesens, L., Snoeck, R., Andrei, G., Balzarini, J., Neyts, J., De Clercq, E.: HPMPC (cidofovir). PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chemistry & Chemotherapy 8 (1997) 1-23.
2. van der Meer, J. T. M., Drew, W. L., Bowden, R. A., Galasso, G. J., Griffiths, P. D., Jabs, D. A., Katlama, C., Spector, S. A., Whitley, R. J.: Summary of the international consensus symposium on advances in diagnosis, treatment and prophylaxis of cytomegalovirus infection. Antiviral Res. 32 (1996) 119-140.
3. Adler, S. P., Baggett, J., McVoy, M.: Transfusion-associated cytomegalovirus infections in seropositive cardiac surgery patients. Lancet 326 (1985) 743-745.
4. Busch, M. P., Lee, T-H., Heitmann, J.: Allogeneic leukocytes hut not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: implications for transfusion support of infected patients. Blood 80 (1992) 2128-2135.
5. Thompson, K. S., Plapp, F. V., Long, N. D., Heenan, T. A.: CMV infection in heart transplant recipients. Transfusion 32 (8S) (1992) S249.
6. Scholz, M., Cinatl, J., Gross, V., Vogel, J.-U., Blaheta, R. A., Freisleben, H.-J., Markus, B. H., Doerr, H. W.: Impact of oxidative stress on human cytomegalovirus replication and on cytokine-mediated stimulation of endothelial cells. Transplantation 61 (1996) 1763-1770.
7. Webster, A., McLaughlin, J. E., Johnson, M. A., Emery, V. C., Griffiths, P. D.: Use of the polymerase chain reaction to detect genomes of human immunodeficiency virus and cytomegalovirus in post-mortem tissues. J. Med. Virol. 47 (1995) 23-28.
8. Bowen, E. F., Wilson, P., Cope, A., Sabin, C., Griffiths, P., Davey, C., Johnson, M., Emery, V.: Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS 10 (1996) 1515-1520.
9. Scholz, M., Auth, M. K. H., Markus, B. H.: The immunological role of biliary epithelial cells in human liver transplant rejection. Transplant Immunol. 5 (1997) in press.
10. Scholz, M., Blaheta, R. A., Cinatl, J., Encke, A., Doerr, H. W., Markus, B. H.: Lymphocytes induce enhanced expression of HLA class I antigens on cytomegalovirus-infected syngeneic human endothelial cells. Human Immunol. 44 (1995) 136-144.
11. Scholz, M., Gooß, A., Blaheta, R. A., Encke, A., Markus, B. H.: Cultured human biliary epithelial cells induce allogeneic lymphocyte activation in vitro: possible relevance in liver transplant rejection. Immunol. Lett. 55 (1997) 27-43.
12. Scholz, M., Cinatl, J. Jr., Blaheta, R. A., Kornhuber, B., Markus, B. H., Doerr, H. W.: Expression of human leukocyte antigens class I and class II on cultured biliary epithelial cells after cytomegalovirus infection. Tissue Antigens 49 (1997) 640-643.
13. Scholz, M., Hamann, A., Blaheta, R. A., Auth, M. K. H., Encke, A., Markus, B. H.: Cytomegalovirus- and interferon-related effects on human endothelial cells: cytomegalovirus infection reduces up-regulation of HLA class II antigen expression after treatment with interferon-gamma. Human Immunol. 35 (1992) 230-238.
14. Sundstrom, J. B., Ansari, A. A.: Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts. Transplant Immunol. 3 (1995) 273-289.
15. Einhorn, L., Gadler, H., Wahren, B.: Adsorption of purified human cytomegalovirus and induction or early antigens in different cells. J. Med. Virol. 10 (1982) 225-234.
16. Myerson, D., Hackman, R. C., Nelson, J. A., Ward, D. C., McDougall, J. K.: Widespread presence of histologically occult cytomegalovirus. Hum. Pathol. 15 (1984) 430-439.
17. Grefte, A., van der Giessen, M., van Son, W., The, T. H.: Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection. J. Infect. Dis. 167 (1993) 270-277.
18. Waldman, J. W., Knight, D. A., Huang, E. H., Sedmak, D. D.: Bidirectional transmission of infectious cytomegalovirus between monocytes and vascular endothelial cells: an in vitro model. J. Infect. Dis. 171 (1995) 263-272.
19. Bolck, F., Machnick, G.: Leber und Gallenwege. In: Doerr, W., Seifert, G., Uehlinger, E. (eds): Spezielle pathologische Anatomie. Springer Verlag, Berlin-Heidelberg-New York, 1978.
20. Fietze, E., Prösch, S., Reinke, P., Stein, J., Döcke, W.-D., Staffa, G., Löning, S., Devaux, S., Emmrich, F., Von Baehr, R., Krüger, D. H., Volk, H.-D.: Cytomegalovirus infection in transplant recipients - the role of tumor necrosis factor. Transplantation 58 (1994) 675-680.
21. Von Willebrand, E. R., Petterson, E., Ahonen, J., Häyry, P.: CMV infection, class II expression, and human kidney allograft rejection. Transplantation 42 (1986) 364-367.
22. Curtsinger, J. M., Liu, Y. N., Radeke, R., Bryon, M. K., Fuad, S., Bach, F. H., Gehrz, R. C.: Molecular analysis of the immune response to human cytomegalovirus glycoprotein B (gB). II. Low gB specific T and B cell responses are associated with expression of certain HLA-DR alleles, J. Gen. Virol. 75 (1994) 301-307.
23. Marshall, G. S., Ricciardi, R. P., Rando, R. F.: An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies. J. Infect. Dis. 162 (1990) 1177-1181.
24. Plotkin, S. A.: Vaccines for varicella zoster virus and cytomegalovirus: recent progress. Science 265 (1994) 1383-1385.
25. Liu, H., Chou, S., Sekulovich, R., Duliège, A.-M., Burke, R. L.: A CMV glycoprotein gB subunit vaccine elicits cross neutralizing antibodies that cross neutralize clinical isolates. 6th International Cytomegalovirus Workshop, March 5-9, 1997, Alabama. Abstr. 43.
26. Gonczol, E., Endresz, V., Kari, L., Berencsi, K., Kari, C., Jeney, C., Pincus, S., Rodeck, U., Meric, C., Plotkin, S. A.: DNA immunization induces human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody as well as phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses and primes immune responses to HCMV proteins. 6th International Cytomegalovirus Workshop, March 5-9, 1997, Alabama. Abstr. 47.
27. Boppana, S., Fowler, K., Pass, R., Mach, M., Britt, W.: Strain specific immune responses and intrauterine transmission of HCMV in immune mothers. 6th International Cytomegalovirus Workshop, March 5-9, 1997, Alabama. Abstr. 45.
28. Mitchell, D. K., Holmes, S. J., Burke, R. L., Sekulovich, R., Tripathi, M., Doyle, M., Duliege, A. M.: Immunogenicity of a recombinant human cytomegalovirus (CMV) gB vaccine in toddlers. 6th International Cytomegalovirus Workshop, March 5-9, 1997, Alabama. Abstr. 50.
29. Kemble, G., Duke, G., Winter, R., Evans, P., Spaete, R.: Derivation of novel, recombinant, live, attenuated CMV vaccine strains. 6th International Cytomegalovirus Workshop, March 5-9, 1997, Alabama. Abstr. 49.
30. Hernandez, L., Chinn, J., Bullock, C., Campbell, L., Albano, A., Contreras, J., Dumont, L., Klingbeil, C.: Safety and pharmacokinetics of a human anti-CMV monoclonal antibody, MSL 109, administered intravitreously to rabbits. 6th International Cytomegalovirus Workshop, March 5-9, 1997, Alabama. Abstr. 149.
31. Pollard, R. B.: CMV retinitis: ganciclovir/monoclonal antibody. Antiviral Res. 29 (1996) 73-75.
32. Gilbert, G. L., Hayes, K., Hudson, I. L., James, J.: Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Lancet 333 (1989) 1228-1231.
33. Eisenfeld, L., Silver, H., McLaughlin, J., Klevjer-Anderson, P., Mayo, D., Anderson, J., Herson, V., Krause, P., Savidakis, J., Lazar, A., Rosenkrantz, T., Pisciotto, P.: Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion 32 (1992) 205-209.
34. Bowden, R. A., Slichter, S. J., Sayers, M., Weisdorf, D., Cays, M., Schoch, G., Banaji, M., Haake, R., Welk, K., Fisher, L., McCullough, J., Miller, W.: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86 (1995) 3598-3603.
35. van Proojen, H. C., Visser, J. J., van Oostendorp, W. R., De Gast, G. C., Verdonck, L. F.: Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br. J. Haematol. 87 (1994) 144-147.
36. Verdonck, L. F., de Graan-Hentzen, Y. C. E., Dekker, A. W., de Gast, G. C.: Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant 2 (1987) 73-78.
37. Busch, M. P., Lee, T-H., Heitman, J.: Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: implications for transfusion support of infected patients. Blood 80 (1992) 2128-2135.
38. Opelz, G., Sengar, D. P. S., Mickey, M. R., Terasaki, P. J.: Effect of blood transfusions on subsequent kidney transplants. Transplant. Proc. 5 (1973) 253-259.
39. Brunson, M. E., Alexander, J. W.: Mechanisms of transfusion-induced immunosuppression. Transfusion 30 (1990) 651-658.
40. Blumberg, N., Heal, J. M., Murphy, P.: Association between transfusion of whole blood and recurrence of cancer. Br. Med. J. 293 (1986) 530-533.
41. Heiss, M. M., Mempel, W., Delanoff, C., Mempel, M., Jauch, K. W., Schildberg, F. W.: Multizentrische Studienplanung zur Immunmodulation bei Tumorpatienten durch die Bluttransfusion. In: Mempel, W., Mempel, M., Heim, M. U., Schwarzfischer, G. (Hrsg.) Eigenbluttransfusion - eine aktuelle Übersicht. Hämatologie 2, Sympomed 1993, München, pp. 119-125.
42. Cinatl, J. Jr., Vogel, J.-U., Cinatl, J., Weber, B., Rabenau, H., Novak, M., Kornhuber, B., Doerr, H. W.: Long-term productive human cytomegalovirus infection of a human neuroblastoma cell line. Int. J. Cancer 65 (1996) 90-96.
43. Nigro, G., Schiavetti, A., Booth, J. C., Clerico, A., Dominici, C., Krzystofiak, A., Castello, M.: Cytomegalovirus-associated stage 4S neuroblastoma relapsed stage 4. Med. Pediatr. Oncol. 24 (1995) 200-203.
44. Spector, S. A., McKinley, G. F., Lalezari, J. P., Samo, T., Andruczk, R., Follansbee, S., Sparti, P. D., Havlir, D. V., Simpson, G., Buhles, W., Wong, R., Stempien, M.: For the Roche Cooperative Oral Ganciclovir Study Group. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N. Engl. J. Med. 334 (1996) 1491-1497.
45. Spector, S. D.: Targeted prevention of CMV disease - implications for individualised therapy. Symposium F. Hoffmann-La Roche Ltd, CMV Disease-Optimising Prevention and Treatment (1996) 12.
46. Dew, W. L., Miner, R. C., Crager, M.: Prevalence of ganciclovir-resistant cytomegalovirus during oral ganciclovir prophylaxis. Abstr. LB16, 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, (1996).
47. Grundy, J. E., Shanley, J. D., Griffiths, P. D.: Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition? Lancet ii (1987) 996.
48. Gümbel, H., Cinatl, J. Jr., Rabenau, H., Vogel, J.-U., Doerr, H. W., Ohrloff, C.: Selektive Hemmung der Replikation des humanen Zytomegalovirus durch Desferrioxamin in vitro und in vivo (Fallbericht). Ophthalmologe 92 (1995) 840-843.
49. Tanaka, K., Koga, Y., Lu, Y.-Y., Zhang, X.-Y., Wang, Y., Kimura, G., Nomoto, K.: Murine cytomegalovirus-associated pneumonitis in the lungs free of the virus. J. Clin. Invest. 94 (1994) 1019-1025.
50. Canpolat, C., Culbert, S., Gardner, M., Whimbey, E., Tarrand, J., Chan, K. W.: Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients. Bone Marrow Transplant 17 (1996) 589-593.
51. Winston, D. J., Imagawa, D. K., Holt, C. D., Kaldas, F., Shaked, A., Busuttil, R. W.: Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation 60 (1995) 1357-1360.
52. Conti, D. J., Freed, B. M., Singh, T. P., Gallichio, M., Gruber, S. A., Lempert, N.: Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplant recipients. Arch. Surg. 130 (1995) 1217-1222.
53. Stals, F. S., Wagenaar, S. S., Bruggeman, C. A.: Generalized cytomegalovirus (CMV) infection and CMV-induced pneumonitis in the rat: combined effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and specific antibody treatment. Antiviral Res. 25 (1994) 147-160.
54. Valenza, M., Czer, L. S., Pan, S. H., Aleksic, I., Freimark, D., Harasty, D. A., Admon, D., Barath, P., Blanche, C., Trento, A.: Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation. J. Heart Lung Transplant. 14 (1995) 659-665.
55. Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., Riddell, S. R.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333 (1995) 1038-1044.